Mode
Text Size
Log in / Sign up

Bioactive plant and fungal metabolites show anticancer activities in preclinical oral cancer modelsPlant and Fungus Compounds Show Promise Against Oral Cancer in Lab Studies

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret preclinical findings on plant metabolites for oral cancer with caution due to PAINS liabilities.

A systematic review examined preclinical evidence on bioactive plant and fungal metabolites—including flavonoids, terpenoids, phenolic metabolites, alkaloids, polysaccharides, and quinones—for oral cancer. The review did not report specific population details, sample sizes, comparators, or follow-up periods. In oral cancer models, these metabolites demonstrated reported activities including suppression of proliferation, induction of apoptosis and autophagy, inhibition of epithelial–mesenchymal transition and angiogenesis, and modulation of tumor metabolism and immune pathways. No effect sizes, absolute numbers, or statistical measures were reported for these outcomes.

Safety and tolerability data were not reported in the review. The authors noted several important limitations: the current evidence base remains largely preclinical, frequently relies on simplified in vitro assays, and has limited pharmacokinetic bridging, toxicity evaluation, and clinically relevant validation. Additionally, several polyphenolic metabolites exhibit pan-assay interference (PAINS) liabilities, which can complicate interpretation of biological activity.

Given the exclusively preclinical nature of the evidence and the identified methodological limitations, these findings cannot support clinical recommendations. The review highlights areas for further research, particularly the need for more robust validation and evaluation of these compounds before any consideration of clinical translation. Funding sources and conflicts of interest were not reported.

Researchers reviewed existing lab studies on natural compounds from plants and fungi, such as flavonoids and alkaloids, to see if they could fight oral cancer. The studies were conducted on cancer cells in dishes and in animal models, not on human patients.

The review found that many of these compounds showed promising anticancer effects in these lab settings. They appeared to slow cancer cell growth, trigger cell death, and interfere with processes that help tumors spread and form new blood vessels.

It is crucial to understand that this evidence is very early and comes entirely from preclinical research. The compounds have not been properly tested for safety or effectiveness in people. Some of these compounds have chemical properties that can interfere with lab tests, making the results less reliable. More research is needed to see if any of these findings could one day lead to new treatments.

What this means for you:
Lab studies show plant compounds may fight oral cancer, but human trials are needed to know if they are safe or effective.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Oral cancer remains a major global health burden. Current therapies are often limited by recurrence, drug resistance, and systemic toxicity. Natural bioactive metabolites, particularly those derived from medicinal plants used in Traditional Chinese Medicine are increasingly investigated as multitarget anticancer leads. In this review, we integrated evidence from studies published between January 2010 and June 2025. We summarize representative flavonoids, terpenoids, phenolic metabolites, alkaloids, polysaccharides, and quinones evaluated in oral cancer models. Reported activities include suppression of proliferation, induction of apoptosis and autophagy, inhibition of epithelial–mesenchymal transition and angiogenesis, and modulation of tumor metabolism and immune pathways. However, the current evidence base remains largely preclinical and frequently relies on simplified in vitro assays. Pharmacokinetic bridging, toxicity evaluation, and clinically relevant validation are still limited. Importantly, several polyphenolic metabolites exhibit pan-assay interference (PAINS) liabilities, requiring cautious interpretation of pathway-level findings. Advances in nano-delivery systems, rational structural optimization, and combination strategies may improve exposure and selectivity. Future work should emphasize PAINS-aware pharmacological rigor, orthogonal target validation, advanced translational models, and biomarker-driven clinical trials to support the development of genuinely druggable natural metabolite candidates for oral cancer management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.